In support of this view, the tumour cells utilized in this study expressed TLR2 and TLR4, and neutralizing antibodies against these receptors indeed inhibited tumour cell migration toward biglycan, which suggested a common mechanism for biglycan to activate cell migration. Here, TLR2 is linked to neoplasm.